Selinexor
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
This trial is open-label, which means that both the participants and health care professionals will know which treatments and doses they are receiving. Participants may continue to receive treatment as long as they do not develop bad side effects, and their myeloma does not get worse.
This clinical trial is being conducted in two different parts. In Part 1, researchers studied how safe and effective two different doses of selinexor were in combination with pomalidomide and dexamethasone compared to elotuzumab, pomalidomide and dexamethasone. Part 1 of this trial is no longer enrolling.
Part 2 of this clinical trial is currently enrolling, and is organized into two different groups, with a total of approximately 220 participants. In Part 2, researchers will compare the best dose of selinexor , pomalidomide and dexamethasone to elotuzumab, pomalidomide and dexamethasone in a larger group of patients.
Participants in Part 2 will be randomly assigned into one of two groups. Both groups will receive treatment organized into 28 day cycles.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 222 patients (estimated)
- Sponsors
- European Myeloma Network
- Collaborators
- Karyopharm Therapeutics
- Tags
- Selective Inhibiton of Nuclear Export (SINE), Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1297
- NCT Identifier
- NCT05028348
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.